Back

The benefits of icosapent ethyl in addressing residual risk: what is the evidence?

13 April 2023 (16:50 - 17:00)
Organised by:
Congress Presentation Part of: New paradigms in the prevention of ASCVD: the role of EPA and triglycerides Lipids Open Access ESC Preventive Cardiology 2023

About the speaker

Photo
Professor Lale Tokgozoglu

Hacettepe University, Ankara (Turkiye)

4 More presentations in this session

Presentation thumbnail
Introduction
Professor F. Visseren (Utrecht, NL)
Slides Video
Presentation thumbnail
Reassessing the role of triglyceride-related residual risk based on recent evidence
Professor R. Hobbs (Oxford, GB)
Slides Video
Presentation thumbnail
Integrating icosapent ethyl in preventive strategies: practical guidance
Professor V. Aboyans (Monaco, MC)
Slides Video
Presentation thumbnail
Discussion
Professor F. Visseren (Utrecht, NL)
Slides Video

Access the full session

Session thumbnail
New paradigms in the prevention of ASCVD: the role of EPA and triglycerides
Video

The Event

Event poster

ESC Preventive Cardiology 2023

13 April 2023 16:50 CET
You may be interested in
thumbnail
Congress Session
New frontiers in ASCVD risk reduction: integrating icosapent ethyl in clinical practice
26 August 2022
thumbnail
Congress Presentation
Key takeaways: addressing residual cardiovascular risk with proven therapies
3 April 2025
thumbnail
Congress Presentation
Update on triglycerides and nutraceuticals
31 August 2025
thumbnail
Congress Presentation
Eicosapentaenoic acid (EPA) treatment increased the ratio to arachidonic (EPA/AA) and reduced adhesion molecule expression in vascular endothelium during inflammation
13 April 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources